Stockscreener 앱 받기
1.99
1.97%
-0.04
시간 외 거래:
1.98
-0.01
-0.50%
전일 마감가:
$2.03
열려 있는:
$2.01
하루 거래량:
275.73K
Relative Volume:
0.59
시가총액:
$188.22M
수익:
$72.76M
순이익/손실:
$35.34M
주가수익비율:
5.3886
EPS:
0.3693
순현금흐름:
$-62.91M
1주 성능:
+1.53%
1개월 성능:
-27.64%
6개월 성능:
+30.92%
1년 성능:
+20.61%
1일 변동 폭
$1.98
$2.0683
1주일 범위
$1.96
$2.12
52주 변동 폭
$1.295
$3.235
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
1.99 | 191.06M | 72.76M | 35.34M | -62.91M | 0.3693 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-07 | 개시 | Lake Street | Buy |
| 2026-01-07 | 개시 | H.C. Wainwright | Buy |
| 2025-01-13 | 개시 | Oppenheimer | Outperform |
| 2022-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-26 | 재개 | JMP Securities | Mkt Outperform |
| 2020-05-13 | 개시 | Stifel | Buy |
| 2020-05-07 | 개시 | SVB Leerink | Outperform |
| 2020-04-22 | 개시 | ROTH Capital | Buy |
| 2020-03-24 | 개시 | SunTrust | Buy |
| 2020-01-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-03-29 | 개시 | Oppenheimer | Outperform |
| 2016-02-01 | 재개 | Oppenheimer | Outperform |
| 2015-10-15 | 개시 | FBR Capital | Outperform |
| 2015-04-23 | 재개 | Jefferies | Buy |
| 2015-04-21 | 개시 | Oppenheimer | Outperform |
| 2014-02-07 | 개시 | MLV & Co | Buy |
| 2009-12-28 | 재확인 | Cantor Fitzgerald | Buy |
| 2009-07-29 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Compugen Ltd 주식(CGEN)의 최신 뉴스
CGEN Q1 2026 Earnings: EPS Misses Estimates amid R&D FocusRevenue Beat Analysis - newsline.com
Compugen Ltd. (CGEN) Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues Development - newsline.com
Compugen Ltd (CGEN) to Present MAIA-Ovarian Trial Progress at Eu - GuruFocus
Compugen to present ovarian cancer trial poster at ESMO - Investing.com UK
Compugen to present ovarian cancer trial poster at ESMO By Investing.com - Investing.com Canada
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 - Yahoo Finance
[EFFECT] COMPUGEN LTD SEC Filing - Stock Titan
AI cancer drug development talk with Compugen streams June 15 - Stock Titan
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development - Yahoo Finance
CGEN STOCK : PRICE RECOVERY | COMPUGEN STOCK (kbWl8ONY7V) - Fathom Journal
CGEN Q1 2026 Earnings: EPS Misses Estimates as Stock Declines on No RevenueEarnings Call Highlights - newsline.com
H.C. Wainwright reiterates Compugen stock rating on ASCO data - Investing.com UK
H.C. Wainwright reiterates Compugen stock rating on ASCO data By Investing.com - Investing.com Canada
CGEN Q1 2026 Earnings: Wider-than-Expected Loss but Early-Stage Pipeline Progress Maintains MomentumFinancial Data - newsline.com
Why The Narrative Around Compugen (NasdaqCM:CGEN) Is Shifting After Analyst Resets And New Views - Yahoo Finance
Compugen Q1 2026 Earnings Call: Complete Transcript - Benzinga
Compugen Shares Slide 5.4% as Key Support Level ApproachesGrowth Stock Picks - newsline.com
Compugen (CGEN) Drops Nearly 4% as Stock Tests Key Support LevelsUndervalued Stocks - The Legal Advocate
CGEN Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ProgressShare Repurchase Impact - newsline.com
Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN) - MSN
Earnings Preview: Compugen to Report Financial Results Pre-market on May 18 - Moomoo
Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Compugen Ltd (CGEN) Stock Price, Trades & News - GuruFocus
Compugen (CGEN) Surges 7.28% as Shares Approach Key Resistance LevelBull Pennant - The Legal Advocate
Compugen Surges 7% as Biotech Stock Tests Key Resistance Levels (CGEN)Positive Gamma - thelegaladvocate.com
Compugen Ltd. Q1 2026 Earnings: Narrowing Losses but Misses EstimatesHot Momentum Watchlist - Newser
Compugen Q1 2026 earnings preview - MSN
Compugen Ltd. (CGEN) Q1 2026 Earnings: Earnings Miss Slightly but Shares Rally on Upcoming CatalystGuidance Update - Newser
CGEN Q1 2026 Earnings: EPS Misses Estimates but Stock Rises 7.28% on Pipeline ProgressOne-Time Loss Impact - newsline.com
Leerink Partners Maintains Compugen(CGEN.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
CGEN Maintains Outperform Rating -- Price Target Lowered to $5.0 - GuruFocus
H.C. Wainwright Maintains Compugen(CGEN.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Compugen Ltd. (NASDAQ:CGEN) Q1 2026 Earnings Call Transcript - Insider Monkey
Compugen Shares Surge 18 Percent Following Better Than Expected Revenue Reports - HarianBasis.co
Compugen (CGEN) Returns To Loss In Q1 2026 And Tests Bullish Profitability Narrative - simplywall.st
Lake Street Maintains Compugen(CGEN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Earnings Call Summary | Compugen(CGEN.US) Q1 2026 Earnings Conference - Moomoo
CGEN: AI-driven immuno-oncology pipeline advances, with strong partnerships and extended cash runway - TradingView
Compugen Ltd at Stifel Virtual Targeted Oncology Forum Transcript - GuruFocus
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program (NASDAQ:CGEN) - Seeking Alpha
Compugen Q1 2026 Deep Dive: EPS Misses by 14.3%, Revenue Down 5% - AlphaStreet
Compugen : Corporate Presentation - marketscreener.com
Compugen (CGEN) Reports Q1 Revenue and Long-Term Financial Stabi - GuruFocus
Compugen Files $400 Million Mixed Shelf - Moomoo
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Compugen Ltd. (NASDAQ: CGEN) files $400M shelf; $100M ATM with Leerink - Stock Titan
Compugen Q1 earnings call highlights - MSN
Compugen Ltd (CGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Compugen Ltd 주식 (CGEN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Levine Zurit | SVP, Business Development |
Apr 24 '26 |
Sale |
3.20 |
2,000 |
6,400 |
29,375 |
| Ophir Eran | President and CEO |
Apr 24 '26 |
Option Exercise |
0.83 |
5,000 |
4,146 |
16,375 |
| Ophir Eran | President and CEO |
Apr 24 '26 |
Sale |
3.20 |
5,000 |
16,000 |
11,375 |
2.60%
0.94%
자본화:
|
볼륨(24시간):